Shares of Imperva Inc (NYSE:IMPV) have earned an average recommendation of “Buy” from the twenty-four research firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation, twelve have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $51.25.

Several equities analysts have recently weighed in on IMPV shares. ValuEngine cut shares of Imperva from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Evercore ISI reaffirmed a “buy” rating and set a $56.00 price target on shares of Imperva in a research note on Friday, May 5th. Zacks Investment Research cut shares of Imperva from a “buy” rating to a “hold” rating in a research note on Tuesday, May 9th. TheStreet raised shares of Imperva from a “d” rating to a “c” rating in a research note on Thursday, May 4th. Finally, Royal Bank Of Canada raised their price target on shares of Imperva from $52.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday, May 5th.

Imperva (NYSE:IMPV) traded up 1.75% during mid-day trading on Friday, hitting $43.60. 730,246 shares of the company’s stock were exchanged. The firm has a 50 day moving average of $47.61 and a 200 day moving average of $45.32. Imperva has a 52 week low of $34.40 and a 52 week high of $57.24. The stock’s market capitalization is $1.47 billion.

Imperva (NYSE:IMPV) last issued its quarterly earnings results on Thursday, July 27th. The software maker reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.05 by $0.15. The business had revenue of $74.44 million for the quarter, compared to the consensus estimate of $74.30 million. Imperva had a negative return on equity of 5.00% and a negative net margin of 4.69%. Imperva’s revenue was up 28.6% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.23) earnings per share. Equities analysts forecast that Imperva will post $0.81 earnings per share for the current fiscal year.

In other Imperva news, insider Amichai Shulman sold 3,089 shares of the firm’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $48.70, for a total transaction of $150,434.30. Following the completion of the sale, the insider now owns 100,151 shares of the company’s stock, valued at approximately $4,877,353.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Sunil D. Nagdev sold 4,857 shares of the firm’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $49.00, for a total value of $237,993.00. Following the sale, the senior vice president now directly owns 16,290 shares of the company’s stock, valued at approximately $798,210. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

A number of large investors have recently made changes to their positions in IMPV. North Run Capital LP increased its stake in Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock worth $30,788,000 after buying an additional 681,772 shares in the last quarter. Clearbridge Investments LLC increased its stake in Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock worth $51,826,000 after buying an additional 403,809 shares in the last quarter. BlackRock Inc. increased its stake in Imperva by 11.3% in the second quarter. BlackRock Inc. now owns 2,124,043 shares of the software maker’s stock worth $101,635,000 after buying an additional 215,170 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Imperva by 8,392.3% in the first quarter. BNP Paribas Arbitrage SA now owns 200,927 shares of the software maker’s stock worth $8,248,000 after buying an additional 198,561 shares in the last quarter. Finally, Eagle Asset Management Inc. increased its stake in Imperva by 17.7% in the second quarter. Eagle Asset Management Inc. now owns 1,279,848 shares of the software maker’s stock worth $61,240,000 after buying an additional 192,625 shares in the last quarter. 92.72% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Imperva Inc (IMPV) Receives Average Rating of “Buy” from Brokerages” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/11/imperva-inc-impv-receives-average-rating-of-buy-from-brokerages.html.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Analyst Recommendations for Imperva (NYSE:IMPV)

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.